Management of Raynaud’s Phenomenon

John D. Pauling

Vasculitis Treatment Update

Keck School of Medicine of USC

K. Ruddy

How do I Recognize and Treat the VEXAS Syndrome?

Cleveland Clinic Medical Specialty Institute

P. Grayson

Are There Factors That Can Guide Treatment Decisions in Newly Diagno…

Cleveland Clinic Rheumatology

A. Villa-Forte

Rheumatology Update for the Generalist in 2024

McMaster University Department of Medicine

R. Mirza

Myths and Misconceptions ANCA Associated Vasculitis

RheumNow

M. Putman

Giant Cell Arteritis in the Arab Region With a Focus on Jordan

Fatima Al Naimat

Cleveland Clinic Rheumatic Case Studies: 32 y/o Male w/ Inflammatory…

Cleveland Clinic Rheumatology

L. Calabrese, J. Gelfand, C. Oddis, J. Cush, A. Kavanaugh, R. Hajj-Ali

What’s Causing the Inflammatory Arthritis & Weight Loss? Why Did a R…

Cleveland Clinic Rheumatology Case Studies

A. Brown

To B or Not to B - CAR-T Cells Enter the Treatment Arena of IMIDS

William Rigby

How Does the Treatment of Behçet’s Disease Differ Based on Disease M…

Cleveland Clinic Rheumatology

G. Hatemi

70 y/o Male With Seropositive RA, ANCA Vasculitis, and ILD: Would An…

Keck School of Medicine of USC

C. Chen

Is There Still a Role for Conventional Immunosuppressive Agents in A…

Cleveland Clinic Rheumatology

C. Langford

Maintenance Rituximab in ANCA-Associated Vasculitis: Dose, Frequency…

Cleveland Clinic Rheumatology

R. Smith

Complement and ANCA Vasculitis

Cleveland Clinic Rheumatology

A. Brown

Diagnosis of ANCA-Associated Vasculitis: Use of ANCA Testing

North Carolina Rheumatology Association

P. Seo

ANCA and Endocarditis

Cleveland Clinic Rheumatology

A. Brown

72 y/o Female With Giant Cell Arteritis, Polymyalgia Rheumatica, and…

Vanderbilt University Medical Center (VUMC)

K. Byram

When Should Biologic Agents be Introduced in Giant Cell Arteritis an…

Cleveland Clinic Medical Specialty Institute

K. Warrington

Bartonella for the Rheumatologist

Cleveland Clinic Rheumatology and Immunology Series

A. Brown